PER 5.33% 7.1¢ percheron therapeutics limited

For General Information, page-2663

  1. 4,336 Posts.
    lightbulb Created with Sketch. 2023
    Givinostat also has been tested in adults with Becker muscular dystrophy. Top-line results from a Phase 2 trial (NCT03238235) showed that treatment failed to reduce muscle scarring, a main trial goal, but its use stopped further muscle shrinkage and fat infiltration, suggesting it may slow or prevent disease progression.

    I wasnt correct in what I said about the adult trial.
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
7.1¢
Change
-0.004(5.33%)
Mkt cap ! $64.91M
Open High Low Value Volume
7.5¢ 7.5¢ 7.1¢ $17.41K 239.5K

Buyers (Bids)

No. Vol. Price($)
1 2531 7.1¢
 

Sellers (Offers)

Price($) Vol. No.
7.4¢ 42959 2
View Market Depth
Last trade - 11.20am 30/07/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.